RT Journal Article
SR Electronic
T1 Whole exome sequencing reveals a wide spectrum of ciliary gene mutations in nonsyndromic biliary atresia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091504
DO 10.1101/2020.05.05.20091504
A1 Wai-Yee Lam
A1 Man-Ting So
A1 Jacob Shujui Hsu
A1 Patrick Ho-Yu Chung
A1 Diem Ngoc Ngo
A1 Pham Anh Hoa Nguyen
A1 Hannah M. Mitchison
A1 Dagan Jenkins
A1 Christopher O’Callaghan
A1 Pak-Chung Sham
A1 Maria-Mercè Garcia-Barceló
A1 Vincent Chi-Hang Lui
A1 Clara Sze-Man Tang
A1 Paul Kwong-Hang Tam
YR 2020
UL http://medrxiv.org/content/early/2020/05/08/2020.05.05.20091504.abstract
AB Biliary atresia (BA) is the most common obstructive cholangiopathy in neonates, often progressing to end-stage cirrhosis. BA pathogenesis is believed to be multifactorial, but the genetic contribution remains poorly defined. We conducted exome sequencing on 89 nonsyndromic BA trios. In 31.5% of the patients, rare and deleterious de novo, homozygous recessive and/or compound heterozygous variants were detected in liver-expressed ciliary genes of diverse ciliary functions. Enrichment of deleterious mutations in liver-expressed ciliary geneset was significant compared to 148 control trios (OR 2.58, 95% CI 1.15-6.07). KIF3B, PCNT and TTC17 are essential for ciliogenesis. Reduced ciliary proteins expression were detected in the BA livers with KIF3B and TTC17 mutations. CRISPR/Cas9-engineered zebrafish knockouts of KIF3B, PCNT and TTC17 displayed reduced biliary flow. Our findings support a larger genetic contribution to nonsyndromic BA risk than expected. Ciliary gene mutations leading to cholangiocyte cilia malformation and dysfunction could be a key biological mechanism in BA pathogenesis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by research grants from the Hong Kong General Research Fund (grant no. 17107314 and 766112 to M.M.G.B., 17105119 to V.C.H.L.) and Li Ka Shing Donation Account - Enhanced New Staff Start-up Packages to P.H.Y.C.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.